PAGE 1
HOUSE BILL 813

J5 ~~EMERGENCY~~ ~~BILL~~ (5lr2785)
ENROLLED BILL
— Health and Government Operations/Finance —
Introduced by Delegates S. Johnson ~~and~~ ~~A.~~ ~~Johnson,~~ A. Johnson, Alston, Bagnall,
Bhandari, Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez,
Martinez, M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Ross, Szeliga,
Taveras, White Holland, Woods, and Woorman

Read and Examined by Proofreaders:

_______________________________________________
Proofreader.
_______________________________________________
Proofreader.

Sealed with the Great Seal and presented to the Governor, for his approval this

_______ day of _______________ at ________________________ o’clock, ________M.

______________________________________________
Speaker.

CHAPTER ______

1 AN ACT concerning

2 ~~Pharmacy~~ ~~Benefits~~ ~~Administration~~ ~~–~~ ~~Maryland~~ ~~Medical~~ ~~Assistance~~ ~~Program~~ ~~and~~
3 ~~Pharmacy~~ ~~Benefits~~ ~~Managers~~
4 Maryland Insurance Administration and Maryland Department of Health –
5 Workgroup to Study Pharmacy Benefits Managers

6 FOR the purpose of ~~altering~~ ~~the~~ ~~reimbursement~~ ~~levels~~ ~~for~~ ~~drug~~ ~~products~~ ~~that~~ ~~the~~ ~~Maryland~~
7 ~~Medical~~ ~~Assistance~~ ~~Program~~ ~~is~~ ~~required~~ ~~to~~ ~~establish~~ ~~and~~ ~~that~~ ~~pharmacy~~ ~~benefits~~
8 ~~managers~~ ~~that~~ ~~contract~~ ~~with~~ ~~a~~ ~~pharmacy~~ ~~on~~ ~~behalf~~ ~~of~~ ~~a~~ ~~managed~~ ~~care~~ ~~organization~~
9 ~~are~~ ~~required~~ ~~to~~ ~~reimburse~~ ~~the~~ ~~pharmacy;~~ ~~altering~~ ~~the~~ ~~definition~~ ~~of~~ ~~“purchaser”~~ ~~for~~
10 ~~purposes~~ ~~of~~ ~~certain~~ ~~provisions~~ ~~of~~ ~~law~~ ~~regulating~~ ~~pharmacy~~ ~~benefits~~ ~~managers~~ ~~to~~
11 ~~include~~ ~~certain~~ ~~insurers,~~ ~~nonprofit~~ ~~health~~ ~~service~~ ~~plans,~~ ~~and~~ ~~health~~ ~~maintenance~~
12 ~~organizations~~ requiring the Maryland Insurance Administration and the Maryland

EXPLANATION: CAPITALS LAW.INDICATE MATTER ADDED TO EXISTING
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
~~Strike~~ ~~out~~ indicates matter stricken from the bill by amendment or deleted from the law by
amendment.
Italics indicate opposite chamber/conference committee amendments.*hb0813*

PAGE 2
2 HOUSE BILL 813

1 Department of Health, in consultation with the Prescription Drug Affordability
2 Board, to convene a workgroup to study certain issues related to pharmacy benefits
3 managers and report to certain committees on or before a certain date; and generally
4 relating to ~~pharmacy~~ ~~benefits~~ ~~administration~~ a workgroup to study pharmacy
5 benefits managers.

6 ~~BY~~ ~~repealing~~ ~~and~~ ~~reenacting,~~ ~~with~~ ~~amendments,~~
7 ~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~
8 ~~Section~~ ~~15–118(b)~~
9 ~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
10 ~~(2023~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2024~~ ~~Supplement)~~

11 ~~BY~~ ~~adding~~ ~~to~~
12 ~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~
13 ~~Section~~ ~~15–118(f)~~
14 ~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
15 ~~(2023~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2024~~ ~~Supplement)~~

16 ~~BY~~ ~~repealing~~ ~~and~~ ~~reenacting,~~ ~~with~~ ~~amendments,~~
17 ~~Article~~ ~~–~~ ~~Insurance~~
18 ~~Section~~ ~~15–1601(s)~~
19 ~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
20 ~~(2017~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2024~~ ~~Supplement)~~

21 ~~BY~~ ~~adding~~ ~~to~~
22 ~~Article~~ ~~–~~ ~~Insurance~~
23 ~~Section~~ ~~15–1632~~
24 ~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
25 ~~(2017~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2024~~ ~~Supplement)~~

26 ~~SECTION~~ ~~1.~~ ~~BE~~ ~~IT~~ ~~ENACTED~~ ~~BY~~ ~~THE~~ ~~GENERAL~~ ~~ASSEMBLY~~ ~~OF~~ ~~MARYLAND,~~
27 ~~That~~ ~~the~~ ~~Laws~~ ~~of~~ ~~Maryland~~ ~~read~~ ~~as~~ ~~follows:~~

28 ~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~

29 ~~15–118.~~

~~[Except]~~ ~~SUBJECT~~ ~~(2)~~30 ~~(b)~~ ~~(1)~~ ~~TO~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~ ~~SUBSECTION~~ ~~AND~~
~~[(2)]~~ ~~(3)~~31 ~~as~~ ~~provided~~ ~~under~~ ~~paragraph~~ ~~of~~ ~~this~~ ~~subsection,~~ ~~the~~ ~~Program~~ ~~shall~~~~EXCEPT~~
~~[maximum]~~32 ~~establish~~ ~~reimbursement~~ ~~levels~~ ~~for~~ ~~the~~ ~~drug~~ ~~products~~ ~~for~~ ~~which~~~~MINIMUM~~
~~Article[,~~33 ~~there~~ ~~is~~ ~~a~~ ~~generic~~ ~~equivalent~~ ~~authorized~~ ~~under~~ ~~§~~ ~~12–504~~ ~~of~~ ~~the~~ ~~Health~~ ~~Occupations~~
~~product].~~34 ~~based~~ ~~on~~ ~~the~~ ~~cost~~ ~~of~~ ~~the~~ ~~generic~~

~~(2)~~ ~~EXCEPT~~ ~~(4)~~ ~~SUBSECTION,~~35 ~~AS~~ ~~PROVIDED~~ ~~IN~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~
~~(1)~~36 ~~MINIMUM~~ ~~REIMBURSEMENT~~ ~~LEVELS~~ ~~ESTABLISHED~~ ~~UNDER~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~
~~NATIONAL~~ ~~AVERAGE~~ ~~DRUG~~37 ~~SUBSECTION~~ ~~SHALL~~ ~~BE~~ ~~AT~~ ~~LEAST~~ ~~EQUAL~~ ~~TO~~ ~~THE~~

PAGE 3
HOUSE BILL 813 3

~~ACQUISITION~~ ~~COST~~ ~~FEE–FOR–SERVICE~~1 ~~OF~~ ~~THE~~ ~~GENERIC~~ ~~PRODUCT~~ ~~PLUS~~ ~~THE~~
~~DEPARTMENT~~2 ~~PROFESSIONAL~~ ~~DISPENSING~~ ~~FEE~~ ~~DETERMINED~~ ~~BY~~ ~~THE~~ ~~IN~~
~~IN–STATE~~ ~~COST–OF–DISPENSING~~ ~~SURVEY.~~3 ~~ACCORDANCE~~ ~~WITH~~ ~~THE~~ ~~MOST~~ ~~RECENT~~

~~[(2)]~~ ~~(3)~~ ~~[If]~~ ~~EXCEPT~~ ~~(4)~~4 ~~AS~~ ~~PROVIDED~~ ~~IN~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~
~~SUBSECTION,~~5 ~~a~~ ~~prescriber~~ ~~directs~~ ~~a~~ ~~specific~~ ~~brand~~ ~~name~~ ~~drug,~~ ~~the~~ ~~reimbursement~~ ~~level~~~~IF~~
~~[cost]~~ ~~NATIONAL~~ ~~AVERAGE~~ ~~DRUG~~ ~~ACQUISITION~~ ~~COST~~6 ~~shall~~ ~~be~~ ~~based~~ ~~on~~ ~~the~~ ~~of~~ ~~the~~
~~FEE–FOR–SERVICE~~7 ~~brand~~ ~~name~~ ~~product~~ ~~PLUS~~ ~~THE~~ ~~PROFESSIONAL~~ ~~DISPENSING~~ ~~FEE~~
~~DEPARTMENT~~8 ~~DETERMINED~~ ~~BY~~ ~~THE~~ ~~IN~~ ~~ACCORDANCE~~ ~~WITH~~ ~~THE~~ ~~MOST~~ ~~RECENT~~
~~IN–STATE~~ ~~COST–OF–DISPENSING~~9 ~~SURVEY.~~

~~(4)~~ ~~PARAGRAPHS~~ ~~(2)~~ ~~(3)~~ ~~TO:~~10 ~~AND~~ ~~OF~~ ~~THIS~~ ~~SUBSECTION~~ ~~DO~~ ~~NOT~~ ~~APPLY~~

~~(I)~~ ~~A~~11 ~~PHARMACY~~ ~~OWNED~~ ~~BY~~ ~~OR~~ ~~UNDER~~ ~~THE~~ ~~SAME~~ ~~CORPORATE~~
~~MANAGER;~~12 ~~AFFILIATION~~ ~~AS~~ ~~A~~ ~~PHARMACY~~ ~~BENEFITS~~ ~~OR~~

~~(II)~~ ~~A~~ ~~PHARMACY.~~13 ~~MAIL~~ ~~ORDER~~

~~(F)~~ ~~THE~~ ~~§~~ ~~15–1632~~ ~~INSURANCE~~ ~~ARTICLE~~14 ~~PROVISIONS~~ ~~OF~~ ~~OF~~ ~~THE~~ ~~APPLY~~ ~~TO~~
15 ~~A~~ ~~MANAGED~~ ~~CARE~~ ~~ORGANIZATION~~ ~~THAT~~ ~~USES~~ ~~A~~ ~~PHARMACY~~ ~~BENEFITS~~ ~~MANAGER~~ ~~TO~~
16 ~~MANAGE~~ ~~PRESCRIPTION~~ ~~DRUG~~ ~~COVERAGE~~ ~~BENEFITS~~ ~~ON~~ ~~BEHALF~~ ~~OF~~ ~~THE~~ ~~MANAGED~~
17 ~~ORGANIZATION.~~~~CARE~~

18 ~~Article~~ ~~–~~ ~~Insurance~~

19 ~~15–1601.~~

~~(1)~~20 ~~(s)~~ ~~“Purchaser”~~ ~~means~~ ~~a~~ ~~person~~ ~~that~~ ~~offers~~ ~~a~~ ~~plan~~ ~~or~~ ~~program~~ ~~in~~ ~~the~~ ~~State,~~
21 ~~including~~ ~~the~~ ~~State~~ ~~Employee~~ ~~and~~ ~~Retiree~~ ~~Health~~ ~~and~~ ~~Welfare~~ ~~Benefits~~ ~~Program,~~ ~~AN~~
~~INSURER,~~ ~~PLAN,~~22 ~~A~~ ~~NONPROFIT~~ ~~HEALTH~~ ~~SERVICE~~ ~~OR~~ ~~A~~ ~~HEALTH~~ ~~MAINTENANCE~~
~~ORGANIZATION,~~23 ~~that:~~

~~[(1)]~~ ~~(I)~~24 ~~provides~~ ~~prescription~~ ~~drug~~ ~~coverage~~ ~~or~~ ~~benefits~~ ~~in~~ ~~the~~ ~~State;~~ ~~and~~

~~[(2)]~~ ~~(II)~~25 ~~enters~~ ~~into~~ ~~an~~ ~~agreement~~ ~~with~~ ~~a~~ ~~pharmacy~~ ~~benefits~~ ~~manager~~ ~~for~~
26 ~~the~~ ~~provision~~ ~~of~~ ~~pharmacy~~ ~~benefits~~ ~~management~~ ~~services.~~

~~(2)~~ ~~“PURCHASER”~~27 ~~DOES~~ ~~NOT~~ ~~INCLUDE~~ ~~A~~ ~~NONPROFIT~~ ~~HEALTH~~
~~THAT:~~28 ~~MAINTENANCE~~ ~~ORGANIZATION~~

~~(I)~~ ~~MODEL;~~29 ~~OPERATES~~ ~~AS~~ ~~A~~ ~~GROUP~~

~~(II)~~30 ~~PROVIDES~~ ~~SERVICES~~ ~~SOLELY~~ ~~TO~~ ~~A~~ ~~MEMBER~~ ~~OR~~ ~~PATIENT~~ ~~OF~~
~~ORGANIZATION;~~31 ~~THE~~ ~~NONPROFIT~~ ~~HEALTH~~ ~~MAINTENANCE~~ ~~AND~~

PAGE 4
4 HOUSE BILL 813

~~(III)~~1 ~~FURNISHES~~ ~~SERVICES~~ ~~THROUGH~~ ~~THE~~ ~~INTERNAL~~ ~~PHARMACY~~
~~ORGANIZATION.~~2 ~~OPERATIONS~~ ~~OF~~ ~~THE~~ ~~NONPROFIT~~ ~~HEALTH~~ ~~MAINTENANCE~~

~~15–1632.~~3

~~A~~4 ~~PHARMACY~~ ~~BENEFITS~~ ~~MANAGER~~ ~~THAT~~ ~~CONTRACTS~~ ~~WITH~~ ~~A~~ ~~PHARMACY~~ ~~ON~~
~~ORGANIZATION,~~ ~~§~~ ~~15–101~~5 ~~BEHALF~~ ~~OF~~ ~~A~~ ~~MANAGED~~ ~~CARE~~ ~~AS~~ ~~DEFINED~~ ~~IN~~ ~~OF~~ ~~THE~~
~~HEALTH~~ ~~–~~ ~~GENERAL~~ ~~ARTICLE,~~6 ~~SHALL~~ ~~REIMBURSE~~ ~~THE~~ ~~PHARMACY~~ ~~AN~~ ~~AMOUNT~~
~~NATIONAL~~ ~~AVERAGE~~ ~~DRUG~~ ~~ACQUISITION~~ ~~COST~~7 ~~THAT~~ ~~IS~~ ~~AT~~ ~~LEAST~~ ~~EQUAL~~ ~~TO~~ ~~THE~~
~~FEE–FOR–SERVICE~~8 ~~PLUS~~ ~~THE~~ ~~PROFESSIONAL~~ ~~DISPENSING~~ ~~FEE~~ ~~DETERMINED~~ ~~BY~~ ~~THE~~
~~MARYLAND~~ ~~DEPARTMENT~~ ~~HEALTH~~ ~~MARYLAND~~ ~~MEDICAL~~ ~~ASSISTANCE~~9 ~~OF~~ ~~FOR~~ ~~THE~~
~~PROGRAM~~ ~~IN–STATE~~10 ~~IN~~ ~~ACCORDANCE~~ ~~WITH~~ ~~THE~~ ~~MOST~~ ~~RECENT~~
~~COST–OF–DISPENSING~~ ~~SURVEY.~~11

12 ~~SECTION~~ ~~2.~~ ~~AND~~ ~~BE~~ ~~IT~~ ~~FURTHER~~ ~~ENACTED,~~ ~~That~~ ~~this~~ ~~Act~~ ~~is~~ ~~an~~ ~~emergency~~
13 ~~measure,~~ ~~is~~ ~~necessary~~ ~~for~~ ~~the~~ ~~immediate~~ ~~preservation~~ ~~of~~ ~~the~~ ~~public~~ ~~health~~ ~~or~~ ~~safety,~~ ~~has~~
14 ~~been~~ ~~passed~~ ~~by~~ ~~a~~ ~~yea~~ ~~and~~ ~~nay~~ ~~vote~~ ~~supported~~ ~~by~~ ~~three–fifths~~ ~~of~~ ~~all~~ ~~the~~ ~~members~~ ~~elected~~ ~~to~~
15 ~~each~~ ~~of~~ ~~the~~ ~~two~~ ~~Houses~~ ~~of~~ ~~the~~ ~~General~~ ~~Assembly,~~ ~~and~~ ~~shall~~ ~~take~~ ~~effect~~ ~~from~~ ~~the~~ ~~date~~ ~~it~~ ~~is~~
16 ~~enacted.~~

17 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
18 That the Maryland Insurance Administration and the Maryland Department of Health, in
19 consultation with the Prescription Drug Affordability Board, shall:

20 (1) convene a workgroup of interested stakeholders, including community
21 pharmacies from both chain and independent settings, pharmacy services administrative
22 organizations, health insurance carriers, plan sponsor representatives, drug wholesalers
23 and distributors, non–pharmacy benefit manager–owned mail order pharmacies, brand
24 name and generic drug manufacturers, pharmacists, pharmacy benefits managers, ~~and~~
25 managed care organizations, and third–party experts in the field of drug pricing in
26 Medicaid;

27 (2) review reimbursement for pharmacists, including:

28 (i) existing Maryland Medical Assistance Program requirements for
29 pharmacy benefits managers and managed care organizations related to dispensing fee
30 reimbursement, pharmacy benefits managers fees charged to pharmacies and the
31 Maryland Medical Assistance Program, transparency in pricing and reimbursement data,
32 specialty drug designations, and appeals processes;

33 (ii) how other states’ pharmacy benefits services operate in
34 Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia;

PAGE 5
HOUSE BILL 813 5

1 (iii) measures that offset the Department’s costs to fund the Medicaid
2 Managed Care Program and adopt NADAC plus the Fee–for–Service Professional
3 Dispensing, including:

4 1. savings associated with NADAC ingredient cost pricing
5 and managed care organizations; and

6 2. pharmacy benefits managers administrative fee
7 consolidation and rebate allocations; and

8 (iv) strategies for adopting pharmacy reimbursement parity and
9 drug pricing transparency;

10 (3) review coverage requirements for specialty drugs, including:

11 (i) which drugs are considered specialty for purposes of formularies
12 across carriers and pharmacy benefits managers; and

13 (ii) what these drugs have in common for purposes of developing a
14 new definition for “specialty drug”;

15 (4) review ERISA exemptions for pharmacy benefits management
16 regulation, including:

17 (i) the scope of Rutledge v. Pharmaceutical Care Management
18 Association and subsequent case law and federal guidance;

19 (ii) how other states have responded to the Rutledge decision; and

20 (iii) what, if any, other State laws should be amended;

21 (5) review the costs associated with pharmacies contracting with
22 commercial plans versus pharmacies contracting with the Maryland Medical Assistance
23 Program;

24 (6) review provisions of State law regarding pharmacy benefit managers,
25 specialty pharmacies, and anti–steering, including:

26 (i) § 15–1611.1 of the Insurance Article related to the use of specific
27 pharmacies or entities and the effect the section has on pharmacy costs in the fully insured
28 market; and

29 (ii) § 15–1612 of the Insurance Article related to reimbursement and
30 the effect the section has on pharmacy costs in the fully insured market;

31 ~~(5)~~ (7) on or before December 31, 2025, submit an interim report on their
32 findings and recommendations to the Senate Finance Committee and the House Health

PAGE 6
6 HOUSE BILL 813

1 and Government Operations Committee, in accordance with § 2–1257 of the State
2 Government Article; and

3 ~~(6)~~ (8) on or before December 31, 2026, submit a final report on their findings
4 and recommendations to the Senate Finance Committee and the House Health and
5 Government Operations Committee, in accordance with § 2–1257 of the State Government
6 Article.

7 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June
8 1, 2025.

Approved:

________________________________________________________________________________
Governor.

________________________________________________________________________________
Speaker of the House of Delegates.

________________________________________________________________________________
President of the Senate.